Gannex Pharma Co., Ltd., a unit of Ascletis Pharma Inc. (ASCLF.PK) Tuesday reported positive interim results from the Phase 2 study of its drug candidate ASC41 to treat patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).
In the Phase 2 study, patients are randomized to receive either ASC41 or placebo for 52-weeks. The interim analysis was conducted after 12-weeks.
At week 12, up to 93.3% patients who received ASC41, achieved at least a 30% relative reduction in liver fat content from baseline. The mean relative reduction in liver fat content from baseline was up to 68.2%.
Further, the company said adverse events were similar among patients receiving ASC41 treatment versus placebo.
For comments and feedback: editorial@rttnews.com